The FDA outlines its ibogaine trial vision, Compass Pathways reveals pricing and slow rollout plans, and early healthcare leaders weigh in—here’s what DMV readers need to know.

The FDA opened a 45‑day comment window on how to safely study ibogaine, seeking input on dosing, cardiac monitoring, ethics, and trial design—without touching legalization debates.

A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

A DEA administrative law judge halted the federal rescheduling proceeding to weigh a new GAO report on agency procedures—delaying a final ruling and keeping the status quo in place for now.

Congress’s PATH Caucus outlines a federal–state roadmap to integrate psychedelic-assisted therapy into U.S. care with clinical safeguards, data tracking and provider standards.

A new GAO report says DEA and FDA lack clear drug-scheduling procedures just as an ALJ reviews moving cannabis to Schedule III and court fights continue.

A 1960s hoax claimed banana peels could get you high. Here’s what actually happened, what the FDA and researchers found, and why rumor-busting still matters in the DMV.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

A new Psychedelic Alpha podcast surveys D.C.’s psychedelic moment, the FDA’s evolving medical framework, and New Zealand’s MDMA prescribers—here’s why the DMV should care.

A small Johns Hopkins pilot gave two psilocybin doses to 20 adults with chronic Lyme symptoms. Participants reported improved sleep and quality of life, and a 40% symptom drop at six months.

A power shift at Lykos Therapeutics could revive MDMA-assisted therapy—and Rick Doblin’s influence. Here’s what’s changing, why it matters, and how DMV residents should watch the next moves.

Psychedelic Alpha reports the FDA held a public hearing on psychedelics. Here’s what that means, what’s unknown, and how DC, Maryland and Virginia should watch the next steps.

What a World Cup controversy reveals about psychedelics, patents, and power—and why DMV patients should watch how culture gets packaged into products and protocols.

Congress faces a December 11 deadline on federal hemp rules while lawmakers debate wildly conflicting regulatory proposals.

New federal signals and Big Pharma interest set the stage as Horizons comes back to New York. Here’s what DMV residents should watch, and how policy, access, and culture may evolve next.

Resilient Pharmaceuticals submits a renewed application for MDMA-assisted PTSD therapy, seeking FDA approval without a fresh Phase 3 trial.

Psychedelic Alpha reports that Risk Evaluation and Mitigation Strategies are likely to shape how FDA-approved psychedelic therapies are delivered. Here’s what to watch.